Market Research Logo

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

222 Reports from BioSeeker Group AB

   
  • Liver Cancer Drug Pipeline Update

    ... over the last years amount to another 65 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 221 different ... Read More

  • Brain Cancer Drug Pipeline Update

    ... diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are today ... Read More

  • Peptides in Oncology Drug Pipeline Update

    ... of ceased drugs over the last years amount to another 148 drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are ... Read More

  • Radiation Therapy in Oncology Drug Pipeline Update

    ... developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 150 drugs. Radiation Therapy In Oncology Drug Pipeline Update lists ... Read More

  • Gene Therapy in Oncology Drug Pipeline Update

    ... accumulated number of ceased drugs over the last years amount to another 105 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... Read More

  • Cytokine Therapy in Oncology Drug Pipeline Update

    ... number of ceased drugs over the last years amount to another 11 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified ... Read More

  • Cellular Therapy in Oncology Drug Pipeline Update

    ... accumulated number of ceased drugs over the last years amount to another 66 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... Read More

  • Biologicals in Oncology Drug Pipeline Update

    ... 2823 biological drugs in 6088 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1050 drugs. Biologicals In Oncology ... Read More

  • Hedgehog Signaling Pathway in Oncology Drug Pipeline Update

    ... 163 companies plus partners developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount ... Read More

  • Wnt Signaling Pathway in Oncology Drug Pipeline Update

    ... today 228 companies plus partners developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years ... Read More

  • Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update

    ... several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas. There are today 248 companies plus partners developing 346 Kit receptor pathway targeting drugs in 1506 developmental projects in cancer. In addition, there are 3 ... Read More

  • B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    ... to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 309 companies plus partners ... Read More

  • IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    ... MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 111 companies plus partners developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer. In addition, ... Read More

  • IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    ... in 1225 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 131 drugs. Il-3 Signaling Pathway In Oncology Drug ... Read More

  • IL-4 Signaling Pathway in Oncology Drug Pipeline Update

    ... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 105 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline Update ... Read More

  • Cell Cycle Targeting in Cancer Drug Pipeline Update

    ... drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cell Cycle Targeting In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on ... Read More

  • Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update

    ... as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. There are today 529 companies plus partners developing 854 cytokine-cytokine receptor interaction interference ... Read More

  • IL-6 Signaling Pathway in Oncology Drug Pipeline Update

    ... in 1579 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 203 drugs. Il-6 Signaling Pathway In Oncology Drug ... Read More

  • TSH Signaling Pathway in Oncology Drug Pipeline Update

    ... will give signaling to NF-kappa B, mitogen activated protein kinases, protein kinase C modules. There are today 226 companies plus partners developing 315 TSH pathway targeting drugs in 1330 developmental projects in cancer. In addition, ... Read More

  • RANKL Signaling Pathway in Oncology Drug Pipeline Update

    ... plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), ... Read More

  • TSLP Signaling Pathway in Oncology Drug Pipeline Update

    ... upon pathogen stimulation. TSLP can also activate dendritic cells, CD4+ T cells and CD8+ T cells. TSLP not only activate the JAK/STAT pathway but also induce phosphorylation of other signaling molecules including PI3K/Akt, ERK1/2 and ... Read More

  • FSH Signaling Pathway in Oncology Drug Pipeline Update

    ... signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity of ... Read More

  • Cancer Stem Cells Drug Pipeline Update

    ... and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 441 ... Read More

  • Calcium Signaling Pathway in Cancer Drug Pipeline Update

    ... drug and the accumulated number of ceased drugs over the last years amount to another 130 drugs. Calcium Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on ... Read More

  • Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update

    ... processes that include hemostasis, the immune response, inflammation, embryogenesis, and development of neuronal tissue. There are four main groups: the integrin family, the immunoglobulin superfamily, selectins, and cadherins. There are today 146 companies plus partners ... Read More

1 2 3 4 6 8 9

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook